Kvien T K, Høyeraal H M, Sandstad B
Scand J Rheumatol. 1985;14(4):346-54. doi: 10.3109/03009748509102037.
Seventy-seven consecutive patients with pauciarticular or polyarticular juvenile rheumatoid arthritis were randomized to treatment with either gold sodium thiomalate (GSTM) or D-penicillamine (PEN) in a parallel 50-week clinical trial. Adverse reactions were reported by or observed in 9 GSTM-treated and 15 PEN-treated patients. Of these, 5 and 7 respectively were withdrawn from the study. Most disease activity measurements were changed in favour of the GSTM group, compared with the PEN group, but significant differences between the treatment regimens were observed for only a few measurements. This possible advantage of GSTM with regard to efficacy was only seen in patients with the polyarticular disease type.
在一项为期50周的平行临床试验中,77例患有少关节型或多关节型幼年类风湿性关节炎的连续患者被随机分为接受硫代苹果酸金钠(GSTM)或青霉胺(PEN)治疗。9例接受GSTM治疗的患者和15例接受PEN治疗的患者报告或观察到了不良反应。其中,分别有5例和7例退出研究。与PEN组相比,大多数疾病活动度测量结果对GSTM组有利,但仅在少数测量中观察到治疗方案之间的显著差异。GSTM在疗效方面的这种潜在优势仅在多关节疾病类型的患者中可见。